USD 0.01
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 73.41 Thousand USD | -55.1% |
2022 | 163.51 Thousand USD | 2080.2% |
2021 | 7500.00 USD | -41.13% |
2020 | 12.74 Thousand USD | 0.0% |
2015 | 118.78 Million USD | 64065.19% |
2014 | 185.11 Thousand USD | 57.09% |
2013 | 117.84 Thousand USD | -21.02% |
2012 | 149.21 Thousand USD | -74.15% |
2011 | 577.29 Thousand USD | 171.74% |
2010 | 212.44 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 FY | 73.41 Thousand USD | -55.1% |
2023 Q4 | 25.86 Thousand USD | 164.7% |
2023 Q3 | 9773.00 USD | -25.71% |
2023 Q2 | 13.15 Thousand USD | 34.61% |
2023 Q1 | 9773.00 USD | -25.71% |
2022 Q4 | 13.15 Thousand USD | -87.57% |
2022 FY | 163.51 Thousand USD | 2080.2% |
2022 Q1 | 42.25 Thousand USD | 463.4% |
2022 Q2 | 13.79 Thousand USD | -67.35% |
2022 Q3 | 105.83 Thousand USD | 667.21% |
2021 Q2 | - USD | 0.0% |
2021 Q4 | 7500.00 USD | 0.0% |
2021 FY | 7500.00 USD | -41.13% |
2021 Q3 | - USD | 0.0% |
2020 FY | 12.74 Thousand USD | 0.0% |
2015 Q3 | 118.27 Million USD | 282894.29% |
2015 Q2 | 41.79 Thousand USD | -87.68% |
2015 Q1 | 339.25 Thousand USD | 711.31% |
2015 FY | 118.78 Million USD | 64065.19% |
2015 Q4 | 126.27 Thousand USD | -99.89% |
2014 FY | 185.11 Thousand USD | 57.09% |
2014 Q4 | 41.81 Thousand USD | -17.08% |
2014 Q2 | 62.27 Thousand USD | 103.47% |
2014 Q1 | 30.6 Thousand USD | 28.66% |
2014 Q3 | 50.42 Thousand USD | -19.02% |
2013 Q1 | 40.03 Thousand USD | 37.89% |
2013 FY | 117.84 Thousand USD | -21.02% |
2013 Q3 | 23.4 Thousand USD | -23.54% |
2013 Q2 | 30.61 Thousand USD | -23.54% |
2013 Q4 | 23.78 Thousand USD | 1.63% |
2012 Q3 | 35.19 Thousand USD | -0.52% |
2012 Q4 | 29.03 Thousand USD | -17.5% |
2012 FY | 149.21 Thousand USD | -74.15% |
2012 Q1 | 49.6 Thousand USD | -18.45% |
2012 Q2 | 35.38 Thousand USD | -28.68% |
2011 Q1 | 439.84 Thousand USD | 0.0% |
2011 Q2 | 23.97 Thousand USD | -94.55% |
2011 Q3 | 52.64 Thousand USD | 119.59% |
2011 Q4 | 60.82 Thousand USD | 15.54% |
2011 FY | 577.29 Thousand USD | 171.74% |
2010 FY | 212.44 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
America Great Health | 661.23 Thousand USD | 88.897% |
Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 99.208% |
Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 99.755% |
Biora Therapeutics, Inc. | 67.14 Million USD | 99.891% |
Bio-Path Holdings, Inc. | 15.84 Million USD | 99.537% |
Better Therapeutics, Inc. | 38.26 Million USD | 99.808% |
Calithera Biosciences, Inc. | 40.68 Million USD | 99.82% |
Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 99.408% |
Gene Biotherapeutics, Inc. | - USD | -Infinity% |
eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 99.783% |
Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 99.787% |
Evelo Biosciences, Inc. | 108.46 Million USD | 99.932% |
Evolutionary Genomics, Inc. | 992.8 Thousand USD | 92.605% |
Finch Therapeutics Group, Inc. | 32.58 Million USD | 99.775% |
Galera Therapeutics, Inc. | 46.95 Million USD | 99.844% |
Innovation1 Biotech Inc. | 1.21 Million USD | 93.956% |
Kiromic BioPharma, Inc. | 19.93 Million USD | 99.632% |
Molecular Templates, Inc. | 63.09 Million USD | 99.884% |
Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 99.473% |
NexImmune, Inc. | 28.16 Million USD | 99.739% |
Orgenesis Inc. | 45.75 Million USD | 99.84% |
Panbela Therapeutics, Inc. | 25.64 Million USD | 99.714% |
PaxMedica, Inc. Common Stock | 16.14 Million USD | 99.545% |
Scopus BioPharma Inc. | 11.71 Million USD | 99.373% |
Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.982% |
Statera Biopharma, Inc. | 28.82 Million USD | 99.745% |
TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 99.612% |
Trevena, Inc. | 38.41 Million USD | 99.809% |
Vaxxinity, Inc. | 56.05 Million USD | 99.869% |
Vaccinex, Inc. | 23.45 Million USD | 99.687% |
Vicapsys Life Sciences, Inc. | 1.04 Million USD | 92.988% |
Viracta Therapeutics, Inc. | 50.69 Million USD | 99.855% |
ZIVO Bioscience, Inc. | 7.27 Million USD | 98.991% |